Vacancies available in support of the COVID-19 National Testing Programme

Home - Business News - Page 7

Vacancies available in support of the COVID-19 National Testing Programme

17 September 2020

Current Vacancies             Our Team            Travel Certification

Vacancies available in support of the COVID-19 National Testing Programme

Vacancies available in support of the COVID-19 National Testing Programme

There’s no doubt that coronavirus is having a devastating effect across the globe.

But here in Northern Ireland there’s a company making a real impact in the fight against COVID-19. And you can be part of it.

Randox Laboratories, in County Antrim, has partnered with the government on its programme for coronavirus testing across Northern Ireland, England, Scotland and Wales.

The programme, which in its first few weeks was focused primarily on staff working within the NHS, and then on key workers, is now available to anyone living across the UK who has symptoms of coronavirus.

Randox are providing high volume laboratory testing of potential COVID-19 samples in its laboratories at the Randox Science Park in Antrim.

It’s an enormous task, but one that Randox is well-equipped to handle. In 2019, Randox manufactured over 3 billion tests and exported to 145 countries. Its new headquarters, the result of a £161 million investment, houses state-of-the-art laboratories and the latest innovations in health diagnostic technology.

The company stepped up to support the government’s testing programme without hesitation.

Across the COVID-19 testing process, a multi-disciplinary team work collaboratively and assiduously to provide optimal support to the national response to COVID-19.

It begins with the production of Randox’s Biochip, a patented testing technology which can run multiple diagnostic tests simultaneously.

Upon identifying the latest strain of coronavirus as a significant global threat, and by drawing on almost 40 years of experience as a world-leading diagnostics company, Randox developed a new Biochip for the diagnosis of COVID-19 in a greatly accelerated time frame of just two weeks. The new Randox Biochip processes two coronavirus tests simultaneously – one specific and one confirmatory – as recommended by the World Health Organisation.

The firm’s team of talented scientists continue to develop these COVID-19 Biochips on an unparalleled scale, in preparation for testing of samples from across the UK.

Meanwhile, specialist engineers design and build the coronavirus testing platforms used to conduct the tests when they arrive at the laboratory.

Randox recently announced it was hiring 160 mechanical, electrical and manufacturing engineers to work on the fast-tracked development of newly designed molecular analysers used to detect the presence of COVID-19.

And the company is also recruiting for positions in Manufacturing and Science, and in particular scientists who have experience in a diagnostic laboratory, in support of Randox’s role within the government testing programme for COVID-19.

These scientists will be exposed to molecular testing techniques including DNA extraction, PCR techniques and Biochip technology, in order to process samples that arrive at the laboratory for testing.

Everyone at Randox has a vital role to play in the practical application of COVID-19 testing.  For Scientists, Engineers and those with experience in Manufacturing, Randox’s recruitment drive is a unique opportunity to make a positive impact in the fight against COVID-19.  Successful applicants will contribute directly both to saving lives and assisting the national recovery from the COVID-19 pandemic. 

To find out more about the positions available for Randox’s COVID-19 testing project, visit  https://randox.getgotjobs.co.uk/

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Randox response to Sunday Times Article 13 September 2020

Randox Logo

   

STATEMENT FROM RANDOX: 13 September 2020

Randox analyse samples and provide Covid-19  test results through the national portal as efficiently as possible, and those tested will receive their results by text and email.    The vast majority of those tested will receive negative or positive results.

Otherwise, a small minority of samples may be voided for reasons such as leaking or damaged tubes, or have time expired.  Those being tested are made aware that samples only remain valid for a limited period once collected, and those periods of validity are fully understood across the planning and logistic process. Randox have no responsibility for the logistics of sample delivery to laboratories.

Should samples enter the laboratory outside that period the results could not be relied upon; the sample could give a false result and would be voided.  In all void circumstances individuals are advised by the national program to seek a retest.  Randox, and the Government planners, take every precaution possible to minimise voids, understanding that each sample is of critical importance.

A test can only be voided once it is processed and reviewed within our laboratory system, including cross referencing each barcode electronically with the national registration database.

Randox Laboratories are committed to supporting the Government’s response to the Covid-19 pandemic and play an important role in national network of Pillar 2 (outside the NHS) laboratories testing those who may be currently infected with Covid-19.  Such testing is critical to the timely identification and containment of Covid-19 outbreaks and to reduce further spread.   It is acknowledged that the success of the testing program is essential to the social and economic well-being of the nation.

To support our operations Randox liaise very closely with Government planners responsible for the national collection and distribution of samples, and have built an additional 30,000 square feet of laboratory space and employed many more staff in order to increase capacity.  At the time of writing further increases in capacity are being implemented and planned.  Decisions on sample distribution across the Pillar 2 laboratory network are made at a national level.

Randox remain committed to effective and timely Covid-19 testing at scale –  this is work of national importance.

Press enquiries should be emailed to randox@newcenturymedia.co.uk 

Randox in the media

Latest News

FAQs


Randox selected to screen travellers to the UAE for Covid-19

02 September 2020

Randox selected to screen travellers to the UAE for Covid-19

Randox Laboratories selected to screen travellers to the UAE for Covid-19, with six sample collection centres across the United Kingdom and Ireland

Randox Laboratories has been selected by Pure Health, the largest laboratory network in the UAE, to test airline passengers flying into the United Arab Emirates, in accordance with the UAE’s requirement for travellers to prove they are not infected with Covid-19. Pure Health has been appointed by the UAE’s government to launch this pioneering project to promote safe travel.

“We are delighted to support Pure Health in their efforts to control the Covid-19 pandemic and facilitate safe travels for passengers flying into the UAE,” said David Adamson, Randox Laboratories, Business Development Manager.

“As one of the largest diagnostic facilities in UK, we are ideally placed to successfully deliver this ambitious initiative, and we are grateful for the trust placed in us.”

Randox Laboratories has already set up six collection centres across United Kingdom and Ireland. The programme is already up and running in London, Liverpool, Glasgow, Belfast, Antrim and Dublin.

“The UAE has trusted Pure Health with safeguarding it against any incoming Covid-19 threats, worldwide, this responsibility requires us to ensure we only partner with verified and accredited facilities around the world, thus why we have partnered with Randox Laboratories, to ensure that the screening process is of the highest quality and to ensure an excellent customer service for the travellers.” said Maria El Houari, International Passenger Screening Project Manager at Pure Health.

The UAE issued regulations that require all travellers flying into the UAE to provide proof of a negative Covid-19 test. Travellers without such a certificate are refused entry into the flight.

The system is similar to the ESTA process in the United States. The traveller visits screening.purehealth.ae, chooses a testing location, selects a time slot, and completes the test at the agreed time and place. Test results are then transmitted to the UAE authorities, who use the data to cross-check arriving travellers against the border control database.

    For further information please email randoxpr@randox.com

    Want to know more about Randox?

    Contact us or visit our homepage to view more.

    Our COVID-19 Products and Services

    HOME TEST

    ANTIBODY TEST

    TRAVEL CERTIFICATE

    LABORATORY TOOLS


    Dr Peter FitzGerald: “Nothing will ever be the same again.”

    Dr Peter FitzGerald: Nothing will ever be the same again.

    An Interview with Ulster Business Editor John Mulgrew in The Belfast Telegraph, in which Dr FitzGerald speaks to John about developing and helping roll out millions of tests for Covid-19, a forever changed society, the high likelihood of a similar pandemic returning and when a vaccine for the virus could be found.

    Dr Peter FitzGerald’s expertise and opinion has probably never been taken as seriously as it has in the last few months.

    “Nothing will be the same again,” he tells Ulster Business. And, of course, he’s right.

    His firm Randox – based in Antrim – has been on the front line of testing for Covid-19 right across the UK and beyond. And as a result, he’s hired hundreds of new staff and built a £30m testing lab to deal with additional deluge of work resulting from a global pandemic unlike anyone here has ever seen.

    “I think there is a reasonable chance there will be more pandemics, with globalisation and increased population,” he told Ulster Business. “I have no idea how much it will come back again in second wave.

    “We know we have the capacity as a company to respond, and respond well. I suspect the country is going to be better prepared… it’s hard to predict.”

    The medical testing giant’s first involvement with the current coronavirus strain began back in January, before it became an increasingly concerning dinner conversation in homes across Northern Ireland.

    “In late January, research called and were looking at doing a test,” Peter said. “We downloaded the genetic sequence of the virus and spent the next two weeks developing a test. We can do it very quickly, as we already had coronaviruses on chip.

    “It was sent to Public Health England, which took a while to prove it. We then got a contract to test for the NHS… we were doing what we thought was for the national good.”

    The initial deal didn’t include all of the UK, but Randox is now also testing Northern Ireland.

    “We do the testing and we have different analysers that do the testing as well, which we sell to labs across the world.”

    The virus has led to a new complete lab being built (in which Peter is pictured in) to deal with the additional testing. “We decided to accelerate the manufacturing in our Randox Science Park in Antrim,” he says.

    As a result, it has hired around 200 staff in the space of six to eight weeks to deal with the surge.

    “Because we had closely related strains of the virus, it was wasn’t so difficult to modify our tests to allow for slightly different variations… once we got the contract we soon realised that we didn’t have enough lab space to deal with the ramp up.

    “We then decided to be 33,000 sq ft of new lab space, and it was needed in three weeks. We got that done – work was 24 hours a day, and seven days a week. It’s now operating well. That has been very important in the process.”

    Randox had a workforce of around 1,450 worldwide before the coronavirus crisis began, but has since taken on around 280 additional staff for a range of roles, partly in ramping up demand for the additional testing.

    “A lot were being taken on a temporary basis but many will be permanent. We are not sure of the final numbers, but well over 100.” Those roles include scientists, manufacturers, and engineers.

    “Nothing will be the same again,” Peter says. “What it has done is heightened the importance of testing. People sometimes don’t know what we do here at Randox… but people now realise.

    “In the end, it’s a good thing. We are advocates of testing. It identities disease before symptoms occur and can save lives in many occasions. It saves lives and saves costs. It fits in with what we have been trying to do for years… as far as we are concerned, it’s the silver lining.

    “We have customers worldwide and other products kept going. We moved around 100 scientists into Covid-related things and then they have gone back to normal jobs as we bring in new people.

    “Some of our R&D projects have changed, new systems and new analysers allow for efficient and accurate testing.”

    Peter says that just a small element of the business has seen a decrease amid the crisis, while other areas around Covid-19 have grown. “Only a small element of core business decreased. But our Covid and other genetic products have increased… overall sales will be up and by end of year normal business up as well.”

    As a result of the latest expansion and growth across the business, generally speaking, Peter says the workforce looks set to climb to 1,650, with around 500-600 based at its main headquarters, just outside Antrim.

    Peter’s also keen to reiterate the importance of Northern Ireland and its people to Randox. “This is our home base. It’s where we do our primary R&D and manufacturing. We also have a facility in Donegal.”

    And, could all of this happen again soon, with a further outbreak or a similarly devastating strain or pandemic?

    “(We are) more prepared and our technology is getting more accepted through bio chips. Early detection is a very important next stage. You don’t want people who have a cough or fever to think they have Covid all the time. That is where testing comes in and that differentiates.”

    Peter says the next stop forward in a bid to address similar future incidents it also understanding how our immune systems work – better.
    “The other major step forward in many ways is understanding the immune system better. How to better respond to infection. This will be very important.

    “Some people are susceptible, and this could be genetic. (It’s about) working on certain genes in those who may have a bad attack. It will prepare humans better, the body’s defence, dealing with it as well.

    “I have a deficiency in a particular gene which means I’m more susceptible to respiratory (conditions) but the spin-off of the gene means I’m less susceptible to certain cancers. This is the issue – it is so complex. One could be a strength and one moment, a weakness.”

    And as for the formulation of a proven vaccine, Peter says: “I would say it would be well into next year.”

      For further information please email randoxpr@randox.com

      Photo Credit Elaine Hill

      Want to know more about Randox?

      Contact us or visit our homepage to view more.

      Our Randox Products and Services

      REAGENTS

      RX SERIES

      ACUSERA

      BIOCHIP


      Update on Sample Kits

      Randox Logo

         

      STATEMENT FROM RANDOX: 07 August 2020

      Randox Laboratories have today taken the decision to recall Covid-19 sample collection kits, following the identification of incomplete EC certification.   On 15th July DHSC placed these kits on hold due to the absence of swab certification from an external supplier. To date, Randox have not been provided with evidence to satisfactorily support the CE marking for these swabs.  So, noting the lack of CE certification by the supplier and that some kits remain in the field at this time Randox has, as a regulatory measure, initiated the recall of those kits used within the National Testing Programme.

      Randox Laboratories will continue to provide high volume Covid-19 testing to the National Testing Programme from their laboratories, based on sample collection kits from other providers.

      DHSC have stated the risk to safety is low and test results from Randox kits are not affected.

      This recall applies only to sample collection kits within the UK National Test and Trace Programme.  Randox private customers or kits are not affected.

      Press enquiries should be emailed to randox@newcenturymedia.co.uk 

      Randox in the media

      Latest News

      FAQs


      COVID-19 Testing Service Testimonial: The Irish Football Association

      News       About Us       COVID-19

       

      25 July 2020

      COVID-19 Testing Service Testimonial: The Irish Football Association

      As we move towards a new ‘normal’ and sporting organisations begin the process of restarting their games, many teams will be wondering how to ensure a safe and reassuring training environment for their players and their staff.

      Thanks to our COVID-19 testing service, The Irish Football Association was able to facilitate a timely and efficient return to play by confirming their players as ‘COVID-safe.’

      Our ‘Back to Business’ programme has enabled the IFA to demonstrate their commitment to their players, their staff, and their fans, as well as get back to business by ensuring the highest level of safety.

      Corinne Lannie, Risk Manager at the Irish Football Association, commented;

      “The test kits were very straightforward to use.  The instructions were clear as was the YouTube guidance video. The recording onto the Randox system was easy and the speed of results was exceptional.

      “The support provided by Paul (Randox Business Development Executive) was amazing – he was extremely helpful and supportive and really went above and beyond.”

      At Randox, we offer two types of testing;

      PCR (diagnostic) testing, and antibody testing, which can give an indication that an individual has been previously infected with COVID-19.

      Sample collection services are available.

      David Hallendorff, Business Relations Manager at Randox Health commented;

      “Collectively we are all working towards a timely return to a more normal society, which will see companies reopening and people returning to work.

      “To facilitate this recovery of the economy, without compromising the health of workers or of the wider general public, workplaces have a responsibility to provide a safe working environment.

      “It is great to see so many companies putting the health of their staff as a priority and taking a proactive approach to testing.

      To find out more about our Back to Business COVID-19 Testing Service, please email info@randoxhealth.com or phone 0800 2545 130

       

       

      Want to find out more?

      Click one of the links below.

      COVID-19 Products and Services

      HOME TEST

      ANTIBODY TEST

      TESTING SERVICE

      LABORATORY TOOLS


      Temporary Precautionary Measure

      Randox Logo

         

      STATEMENT FROM RANDOX: TEMPORARY PRECAUTIONARY MEASURE

      16 July 2020

      As an immediate precautionary measure we have temporarily suspended distribution of sample collection kits using one particular batch / supplier of swabs. This is a temporary measure and does not apply to our private business which uses a different supplier of swabs.

      Test results from Randox kits are not affected.

      For more information please contact the Randox PR team by emailing randoxpr@randox.com

       

      Randox in the media

      Latest News

      FAQs


      Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

      News       About Us       COVID-19

       

      29 June 2020

      Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

      Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

      In a recent Opinion Piece in The Daily Telegraph, our Managing Director Dr Peter FitzGerald stressed the value of diagnostics, the important role it plays in public health, and the contribution it has made specifically during the COVID-19 pandemic.

      Whilst regrettable that it has taken a pandemic to bring the health diagnostics sector into focus, it is a positive step forward for healthcare that the huge national and international scope of our sector is now rightly acknowledged.

      Indeed, Dr FitzGerald’s commentary was acknowledged by both the Secretary of State for Health, Matt Hancock, and the Minister for Innovation, Jim Bethell.

      The Secretary of State noted that “Randox have played a vital role in building our global-scale diagnostics capacity.”

        It is clear that the diagnostics industry, inclusive of the work Randox has done in the field, has had a positive impact in the fight against COVID-19. We know that testing at scale is the most effective way to both save lives, and ensure a timely return to a more normal society.

        We are very proud of our staff, for their ongoing support, and for their commitment to the work that we do, which is making a real and positive difference.

        You can read Dr FitzGerald’s full Opinion Piece for The Daily Telegraph, on our own website, by clicking here.

        For further information please contact randoxpr@randox.com or phone 028 9442 2413

        Want to know more about Randox?

        Contact us or visit our homepage to view more.

        Our Randox Products and Services

        REAGENTS

        RX SERIES

        ACUSERA

        BIOCHIP


        COVID-19 has shown UK leadership on diagnostics; we can now become a world leader

        News       About Us       COVID-19

         

        25 June 2020

        COVID-19 has shown UK leadership on diagnostics

        COVID-19 has shown UK leadership on diagnostics; we can now become a world leader

        An Opinion Piece by Dr Peter FitzGerald, Managing Director of Randox Laboratories, in The Daily Telegraph

        When I founded Randox Laboratories in 1982 in Antrim, Northern Ireland, I could not have envisaged that today we would be manufacturing more clinical diagnostic products than any other company in the UK. Whilst I am incredibly proud that Randox is taking a leading role in the national Covid-19 testing effort, it is deeply regrettable that it has taken this pandemic to bring the UK’s health diagnostics sector into focus.

        The pandemic represents the biggest diagnostics and health infrastructure challenge of modern times.  It has forced and necessitated a herculean collaborative effort from Government, the NHS and the private sector. This partnership has delivered a new trust and information sharing network which bodes well for the future.

        Ministers now know what we can do and rightly acknowledge the huge national and international scope of our sector and for global UK leadership and new skilled jobs.  The Government is right to highlight and reflect that too many of these critical sectors and supplies have been allowed to be offshored in recent years. This has consequently had implications for patient care and the support available for health workers.

        In March, the World Health Organisation’s Director General, Tedros Adhanom Ghebreyesus, said that he had a simple message to countries on how to deal with the COVID-19 outbreak that was sweeping the globe, this message was ‘Test, test, test.’ In the UK, mass testing was, at that time, simply not possible. Indeed, the Health Secretary, Matthew Hancock, acknowledged  that it was the lack of a significant domestic diagnostic industry that had impeded the Government’s initial efforts on testing, which is why we were behind Germany and other states.  He was right and much has already been done to re-shore capacity and re-set this policy alongside understanding the importance for future British sector leadership.

        Going forward, we can and must deliver a new and much tighter partnership between the NHS and private sector across diagnostics and preventative healthcare. Improved communication, co-operation and partnerships will grow British sector expertise, jobs and skills.  The potential for British leadership and success here is huge.

        Earlier this month, I had the pleasure of welcoming Northern Ireland Secretary, Brandon Lewis MP to see our new £30m specialist Covid-19 testing hub at the Randox Science Park in Northern Ireland.  This investment will create 200 new science, engineering and manufacturing jobs at the facility on top of our existing workforce. It was fast-tracked over the space of four weeks and is the first step in a wider diagnostics investment programme as part of Randox’s efforts to enhance our national Covid testing capacity.

        A wider appreciation of the value and resource support for diagnostics testing and preventative health policy is now overdue and timely especially when you consider that seventy per cent of all medical decisions are based on the results of lab tests.  This testing must now account for more than the two per cent of the national healthcare budget.   Alongside our major focus on R&D, our scientists work on pioneering research into a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease. With around twenty five percent of turnover reinvested in R&D, Randox has more new tests in development than any other diagnostic company.  Our products are used across hospitals and veterinary laboratories, food testing, forensic toxicology and life sciences.

        Randox labs have spent over £305 million researching the thousands of biomarkers present in our bodies and have identified the gold standard in testing. Our patented Biochip Array Technology has revolutionized the diagnostics industry by offering a unique testing platform which allows multiple tests to be carried out from a single patient sample. On Covid, we have been able to include two tests on the same biochip; one specific and one confirmatory as recommended by the World Health Organisation.

        The ambition and determination to build a world-beating British diagnostics sector is overdue and right.  It offers so many advantages ranging from a healthier and happier population which lives longer to more skilled jobs in a sector which works hand in glove with our world beating academia and NHS.  The pandemic has rightly brought the UK’s diagnostics capability into sharp focus, and it is paramount that when we move to a post-Covid world, we take what we have learned from this crisis and build a self-reliant sector fit for the future.

          For further information please email randoxpr@randox.com

           

          Want to know more about Randox?

          Contact us or visit our homepage to view more.

          Our Randox Products and Services

          REAGENTS

          RX SERIES

          ACUSERA

          BIOCHIP


          Randox announces its £30m investment in specialised COVID-19 testing lab

          News       About Us       COVID-19

           

          03 June 2020

          Randox invests £30m and 200 new jobs in specialised COVID-19 testing lab

          Randox invests £30m and 200 new jobs in specialised COVID-19 testing lab

          As part of efforts to enhance its national testing capacity, global diagnostics company Randox has announced an investment of £30m in a new specialised COVID-19 testing hub.

          The healthcare firm, which is currently conducting COVID-19 tests as part of the national testing programme, announced its investment in the new facilities based at the Randox Science Park in Antrim, Northern Ireland, during a visit yesterday by the Secretary of State for Northern Ireland, The Rt Hon Brandon Lewis CBE.

          The specialised laboratory, the development of which was fast-tracked over the space of four weeks, is the first step in a wider diagnostics investment programme from Randox.

          Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

          “The national testing programme, as a collaborative effort by government and various partners within industry, has increased testing capacity at an unparalleled speed – by installing a network of drive-through testing centres, introducing home testing kits, and now, opening this specialised lab at the Randox Science Park in Northern Ireland.

          “An incredible amount of work has gone into making this cutting-edge testing facility a reality in a relatively short space of time, as we know that effective testing is the most effective way to both save lives and promote a timely return to a more normal society.”

          The opening of the new laboratory at the Randox Science Park follows the company’s announcement that it is recruiting new staff across Science, Engineering and Manufacturing in support of its role within the national testing programme.

          The 200 new positions will be involved in the testing of potential COVID-19 samples, as well as the construction of 200 new state-of-the-art diagnostic analysers which will significantly increase Randox’s capacity for COVID-19 testing.

          Dr FitzGerald continued;

          “Now that we have in place the infrastructure and laboratory space required to enhance our testing capacity, we look forward to implementing the next step in our COVID-19 investment programme.

          “By accelerating the build schedule for new specialised equipment, and hiring 200 associated workers across Science, Engineering and Manufacturing we will further enhance the government’s national testing scheme, as well as facilitate testing more broadly across the general populace.”

          Secretary of State Brandon Lewis MP welcomed the new investment saying:

          “I was impressed during my visit with the dedication of staff and the top-class facilities at Randox. This investment will help support the UK’s nationwide effort to fight the coronavirus and ultimately save lives.”  

          Dr FitzGerald concluded;

          “I would also like to take this opportunity to pay tribute to all my colleagues at Randox who continue to work assiduously to process such a high volume of tests in a timely manner.

          “I know I speak on behalf of everyone when I say we appreciate all your hard work and the vital role you play in the practical application of COVID-19 testing.”

            For further information please email randoxpr@randox.com

            Want to know more about Randox?

            Contact us or visit our homepage to view more.

            Our Randox Products and Services

            REAGENTS

            RX SERIES

            ACUSERA

            BIOCHIP


            Request a meeting
            ×
            Make an Enquiry - RX series
            ×
            Make an Enquiry - Reagents
            ×
            Kit Insert Request - Reagents
            • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
            ×
            Kit Insert Request - Reagents
            • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
            ×
            Make an Enquiry - Reagents
            ×
            Make an Enquiry - Quality Control
            ×
            Make an Enquiry - RIQAS
            ×
            Make an Enquiry - RIQAS
            ×
            Make an Enquiry - Quality Control
            ×
            Make an Enquiry
            • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
            ×
            Make an Enquiry - Biochip
            • This field is for validation purposes and should be left unchanged.
            ×
            Make an Enquiry - Molecular
            • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
            • This field is for validation purposes and should be left unchanged.
            ×
            Make an Enquiry - Future Diagnostics
            ×
            Make an Enquiry - RX series (Product)
            ×
            Make an Enquiry - Quality Control
            • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
            ×
            Make an Enquiry - RIQAS
            • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
            ×
            Make an Enquiry - Reagents
            • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
            ×
            Por favor, introduzca sus datos para ver nuestro último seminario
            ×
            Wyślij zapytanie
            • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
            ×
            Wyślij zapytanie
            • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
            ×
            Wyślij zapytanie